Alto Neuroscience (ANRO) Short term Debt (2024 - 2026)

Alto Neuroscience (ANRO) reported Short term Debt of $2.1 million for Q1 2026, up 265.13% sequentially from $585000.0 in Q4 2025.

Alto Neuroscience (ANRO) Short term Debt (2024 - 2026) Analysis & Trends

Alto Neuroscience (ANRO) has 3 years of Short term Debt data on file, last reported at $2.1 million in Q1 2026.

For the quarter ending Q1 2026, Short term Debt changed N/A year-over-year to $2.1 million; the trailing twelve-month figure through Mar 2026 stood at $2.1 million (changed N/A YoY), and the FY2025 full-year result was $585000.0, changed N/A from the prior year.
Short term Debt grew to $2.1 million in Q1 2026, from $585000.0 in the prior quarter.
In the past five years, Short term Debt ranged from a high of $3.5 million in Q3 2024 to a low of $585000.0 in Q4 2025.
A 3-year average of $1.9 million and a median of $2.1 million in 2026 frame the typical range for Short term Debt.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Alto Neuroscience	881.86 Mn	881.86 Mn	-

Download Data